BioCryst Pharmaceuticals, Inc. announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients. During the investigation, the company will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials. Patients currently enrolled in the trials are continuing on study drug at this time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.27 USD | +2.64% | -3.17% | -28.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.71% | 858M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials